Idexx Laboratories Inc (IDXX) Financial Statements
Historical financial data — 40 statements covering FY2016–FY2025
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline...
Idexx Laboratories Inc's revenue increased 10.4% year over year, from $3.90B to $4.30B.
Net income increased 19.3% over the same period, from $887.9M to $1.06B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 142% in total.
Total debt decreased by 16.7% to $374.8M.
The debt-to-equity ratio stands at 0.23, indicating a conservative leverage profile.
Operating cash flow grew 27.2% to $1.18B.
Idexx Laboratories Inc maintains a strong net profit margin of 24.6%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2023 | $1.84B+104.8% | $438.3M | $1.12B | $576.5M | $384.2M | $2.87B | $696.8M | $1.09B |
| Q3 FY2023 | $2.76B+49.7% | $650.5M | $1.66B | $851.8M | $656.7M | $3.09B | $618.8M | $1.30B |
| Q1 FY2024 | $964.1M-65.1% | $235.6M | $593.1M | $299.0M | $198.6M | $3.35B | $620.8M | $1.57B |
| Q3 FY2024 | $2.94B+205.3% | $671.7M | $1.81B | $866.7M | $667.0M | $3.35B | $524.8M | $1.62B |
| Q1 FY2025 | $998.4M-66.1% | $242.7M | $623.4M | $316.5M | $238.0M | $3.21B | $449.8M | $1.45B |
| Q2 FY2025 | $2.11B+111.1% | $536.7M | $1.32B | $689.6M | $423.7M | $3.33B | $449.8M | $1.46B |
| Q3 FY2025 | $3.21B+52.4% | $811.3M | $2.00B | $1.04B | $826.0M | $3.39B | $374.8M | $1.56B |
| Q1 FY2026 | $1.14B-64.5% | $278.4M | $722.7M | $362.6M | $266.2M | $3.39B | $299.9M | $1.56B |
Balance Sheet Summary (Latest Period)
Total Assets
$3.35B
Total Liabilities
$1.75B
Total Equity
$1.61B
Cash & Equivalents
$180.1M
Total Debt
$374.8M
Current Assets
$1.41B
Current Liabilities
$1.15B
Retained Earnings
$6.39B